A

agilon health

Value-based primary care platform for seniors

Overview

agilon health builds a Medicare-focused value-based primary care network. It partners with independent primary care physicians to deliver senior care through a unified operating platform that connects payors, physicians, and patients. The platform combines people, processes, and technology to help physician partners close gaps in care, integrate with payors, and grow their practices, while enabling predictable margins and improved patient experience. Unlike models that push physicians to join large owned practices, agilon health keeps clinicians independent and supports them with coordinated care delivery and financial certainty. The company’s goal is to improve health outcomes for seniors by expanding access to quality primary care, aligning incentives across physicians, payors, and patients, and driving value-based care at scale.

Work here?Claim your company

About agilon health

Simplify's Rating
Why agilon health is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & AnalyticsEnterprise SoftwareHealthcare

Company Size

501-1,000

Company Stage

IPO

Headquarters

Long Beach, CA

Founded

2016

Get referred to agilon health

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Q3 2026 revenue hit $1.52 billion, and EBITDA turned positive at $63.7 million.
  • The Jackson Clinic expanded into agilon's Senior Health Connect ACO on September 30, 2026.
  • Management raised 2026 guidance to $5.88 billion revenue and $150 million adjusted EBITDA.

What critics are saying

  • A 2024-2026 securities class action in Texas keeps management distracted and expensive.
  • Membership fell to 566,000 in Q3 2026 after market exits and tighter contracting.
  • Dependence on 2027 contract renewals makes 2028 growth vulnerable if physicians reject pricing.

What makes agilon health unique

  • agilon health's Senior Health Connect ACO linked 30-plus physician groups across Medicare populations.
  • Its AI-enabled data pipeline and clinical pathways target CHF, COPD, lung health, and dementia.
  • The model preserves independent primary care ownership while shifting contracts to full-risk value-based care.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1.1B

Above

Industry Average

Funded Over

1 Rounds

IPO funding comparison data is currently unavailable. We're working to provide this information soon!
IPO Funding Comparison Coming Soon

Benefits

  • Remote Work Options

Stock Price

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Nov 8th, 2026
Agilon health Q3 revenue hits $1.52B, beating estimates, and full-year guidance rises to $5.88B

Agilon health reported third-quarter revenue of $1.52 billion, up 5.9% year on year and ahead of analyst estimates of $1.46 billion. Adjusted EBITDA reached $63.68 million, a 4.2% margin, and operating margin rose to 1.6% from -9.1% a year earlier. The company raised its full-year revenue guidance to $5.88 billion at the midpoint from $5.82 billion. It expects full-year EBITDA of $150 million at the midpoint. Chief executive officer Tim O'Rourke credited technology-enabled clinical pathways and data infrastructure investments for cutting unnecessary medical costs. Customers grew to 566,000 from 549,000 in the previous quarter. O'Rourke said most partnerships signed in 2027 would contribute from 2028, after a 12-18 month onboarding period. He added that agilon is focused on risk-based contracts in new markets. Shares trade at $112.50, up from $96.23 before the results.

Seeking Alpha
Nov 5th, 2026
Agilon raises 2026 outlook to $5.88B revenue and $150M adjusted EBITDA while expecting 40%-50% ACO membership growth in 2027.

Agilon raises 2026 outlook to $5.88B revenue and $150M adjusted EBITDA while expecting 40%-50% ACO membership growth in 2027. Earnings Call Insights: agilon health (AGL) Q3 2026 Management view. * CEO Timothy O'Rourke said, "agilon exceeded our third quarter guidance across key financial metrics" and added, "we are increasing our full year 2026 guidance," tying the update to progress on "improving performance at the physician and market level" and "reducing unnecessary variability." * CEO O'Rourke emphasized technology-enabled clinical pathways as core execution priorities, saying, "We continue to advance our evidence-based clinical pathways, including our programs for CHF, lung health and dementia" and that the company is "continuing to roll out virtual pharmacy across our markets to drive greater adherence to GDMT." * On quality performance, CEO O'Rourke said, "agilon increased gap closure by 3% versus prior year" and "consistent with prior year, achieved a 4.2-star performance for quality measures used by our contracted health plans," while noting, "in measurement year 2025, nationally, we expect 75% of our members to be in 4-plus star plans for payment year 2028." * CEO O'Rourke positioned ACO expansion as a near-term growth vector, stating, "we expect ACO membership to grow approximately 40% to 50% in 2027" and highlighting "3 relationship expansions for nearly 50,000 MSSP members." * CFO Jeffrey Schwaneke attributed the raised outlook to operating and medical-cost dynamics, saying, "The positive results and increase to our full year guidance were driven by better-than-expected performance in the burden of illness and clinical pathways initiatives and favorable medical expense development in the first half of 2026." Outlook. * CFO Schwaneke updated full-year 2026 targets, saying, "Using the midpoint of our guidance ranges for the full year 2026, we now expect revenue of approximately $5.88 billion, medical services expense ratio of 90.4% and adjusted EBITDA of approximately $150 million," and added the guide assumes "a prudent assumption for cost trends in the 7% range for the remainder of the year." * CFO Schwaneke increased the ACO contribution expectation, stating full-year "ACO REACH adjusted EBITDA expectations" are now "between $40 million to $45 million." * For 2027, CFO Schwaneke provided preliminary contracting color: "we currently anticipate we will see a favorable benefit in 2027, albeit more modest than we saw in 2026." * CFO Schwaneke also tied 2027 ACO scaling to earnings progression, saying, "we anticipate growing from approximately 110,000 members today to approximately 160,000 in 2027" and "anticipate ratable improvement in baseline ACO adjusted EBITDA performance based on this growth." Financial results. * CFO Schwaneke reported Medicare Advantage membership "at the end of the third quarter was 454,000" and said the year-over-year decline "reflects previously disclosed market exits related to our disciplined profitability-focused approach to contracting in 2026 and measured approach to growth." * CFO Schwaneke reported Q3 revenue, stating, "Revenue for the third quarter was approximately $1.5 billion," and attributed the increase to "more constructive rates for 2026 from the CMS benchmark, favorable payer contracting and higher revenue associated with improved diagnosis, assessment and treatment" including burden-of-illness program impacts. * CFO Schwaneke introduced a new core metric and reported Q3 performance: "we will now be providing a medical services expense ratio, or MSER, as a core metric" and "For the third quarter, the MSER was 88.5% compared to 104% in the third quarter of 2025." * CFO Schwaneke reported profitability improvement, saying, "Adjusted EBITDA for the third quarter was $64 million compared to negative $91 million in the third quarter of 2025." * CFO Schwaneke reported liquidity and cash outlook changes: "we ended the quarter with $312 million in cash and marketable securities" and "We are increasing our year-end cash outlook and now expect year-end 2026 cash of at least $175 million." Q&A. * Eduardo Ron, Truist Securities, Inc., Research Division: asked whether external growth discussed for 2028 implies contracting activity in 2027 and when impacts would show up; CEO O'Rourke responded, "I would think about it as signing in 2027 for 2028 impact." * Eduardo Ron, Truist Securities, Inc., Research Division: asked for an update on cost trend; CFO Schwaneke said, "the first half has restated favorably into the low 6% range" and added, "we've recorded roughly 7% cost trend in Q3." * Ryan Langston, TD Cowen, Research Division: asked whether new-market deals would start with care coordination fees; CEO O'Rourke said, "We would not be looking at care coordination" and "I would not look at us moving into care coordination fees, but looking at risk," while CFO Schwaneke added, "we have confidence in our underwriting model as we head into 2028 and think about growth." * Ryan Langston, TD Cowen, Research Division: asked about clinical pathway opportunities over 1-2 years; CEO O'Rourke cited "plenty of room to go with our CHF clinical pathway," said virtual pharmacy is at "about 25% of our partners," and added dementia and lung health are rolled out to "about 1/3 of our markets." * Ye Yuan, Barclays Bank PLC, Research Division: asked if agilon participates in payer Stars upside as plans recover; CFO Schwaneke answered, "yes," adding, "we contract based on a percent of premium." Ye Yuan then asked about Q4 seasonality assumptions; CFO Schwaneke said, "fourth quarter is generally our lowest earnings quarter" and added, "we have a 7% cost trend embedded in our guide in that quarter." * Jack Slevin, Jefferies LLC, Research Division: asked what is driving revenue and cost performance; CFO Schwaneke pointed to "clinical pathways" delivering "higher revenue performance" and said, "we've had favorable development from 2025 dates of service" plus first-half cost trend coming in lower than initial assumptions. * Jack Slevin, Jefferies LLC, Research Division: asked about ACO penetration within existing partners; CEO O'Rourke said, "we have the ACO business with about half of our partners today" and described "a continued opportunity in 2027 and beyond to get deeper in that space." * Amir Farahani, Evercore ISI Institutional Equities, Research Division: asked whether the guidance raise largely reflects Q3 upside; CFO Schwaneke bridged the change and said, "The Q3 beat was roughly $64 million" and "the midpoint of roughly $150 million" reflects timing shifts and "the risk adjustment improvement" including "a fourth quarter component, roughly $7 million." Amir Farahani then asked why 2027 contracting benefit is expected to be more modest; CFO Schwaneke said, "we touched 80% of our contracts last year" and in 2027 "it's really that 20% we're focused on getting in the economics." * Matthew Mardula, William Blair & Company L.L.C., Research Division: asked about enhanced data pipeline coverage; CFO Schwaneke said, "we are roughly in the - close to the mid-80% range" and added, "long term, we'd love to be in the low to mid-90s" with the remainder driven by "a cost-benefit analysis." Sentiment analysis. * Analyst tone was slightly positive, with multiple questions focused on sustainability and mechanics of the raise, contracting, and seasonality (for example, Amir Farahani asked, "have your underlying expectations for Q4 improved as well?"). * Management tone was positive and execution-focused in prepared remarks, led by statements such as CEO O'Rourke's "we are increasing our full year 2026 guidance," and remained controlled and explanatory in Q&A (for example, CFO Schwaneke's repeated framing around "prudent" reserving and visibility). * Versus last quarter, the current call carried more emphasis on ACO growth specifics and new reporting metrics (MSER), while last quarter emphasized leadership transition context (CEO O'Rourke's introduction) and gave quarterly guidance that included "break-even adjusted EBITDA" for Q3. Quarter-over-Quarter comparison. * Management in Q3 reiterated the same core operational themes from Q2 (reducing variability, scaling clinical pathways, strengthening data/AI), but added more explicit ACO growth framing for 2027, including "approximately 40% to 50%" ACO membership growth. * Financial framing shifted from Q2's focus on medical margin and Q3 guidance to Q3's focus on MSER as "a core metric" and a full-year adjusted EBITDA midpoint raised to "approximately $150 million" from the prior quarter's midpoint of "approximately $85 million." * Analyst questioning remained centered on cost trend and contracting; Q3 added more probing on the "raise" bridge and Q4 seasonality, while Q2 included more early contracting-process questions and membership puts-and-takes for 2027. Risks and concerns. * CFO Schwaneke highlighted visibility and reserving constraints, stating, "we have limited paid claims visibility sitting here at the end of the quarter," and noted Q3 trend reflects "our prudent reserving approach." * CEO O'Rourke described contracting exposure as a key execution area, saying 2027 contracting "will address approximately 50% of our book of business" and the goal is "reducing risks outside our control while securing economics supportive of the value we provide." * CFO Schwaneke described ongoing Part D risk reduction as part of the contracting posture, saying, "we were 30% with full risk in Part D on 2025, down to roughly 15% this year," and added, "we'll substantially reduce that risk as we go into next year." Final takeaway. agilon's management characterized Q3 as a continuation of improving execution, citing raised full-year 2026 guidance anchored by burden-of-illness and clinical pathway performance, favorable medical expense development, and stronger ACO contributions. Leadership emphasized scaling repeatable clinical pathways (including CHF, dementia, and lung health), adopting MSER as a core performance metric, and pursuing disciplined contracting and measured growth, while outlining a specific expectation for ACO membership expansion in 2027 and describing external market growth as a 2028 impact driven by contracts signed in 2027. Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. More on agilon health. Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Yahoo Finance
Nov 4th, 2026
Agilon swings to $34.9M Q3 profit as $1.52B revenue beats forecasts

Agilon Health Inc. reported third-quarter net income of $34.9 million on Wednesday, reversing a loss in the same period a year earlier. That equals $1.97 per share. Revenue reached $1.52 billion. Both figures beat Wall Street forecasts: analysts surveyed by Zacks Investment Research had expected a loss of $2.01 per share and revenue of $1.45 billion. The Westerville, Ohio-based senior-focused health care company expects full-year revenue of $5.87 billion to $5.89 billion. Its shares have risen fivefold over the past year, hitting $95.76 in the final minutes of trading on Wednesday.

BioPharma Watch
Sep 30th, 2026
agilon health and The Jackson Clinic advance their partnership through Senior Health Connect ACO.

agilon health and The Jackson Clinic advance their partnership through Senior Health Connect ACO. Key Takeaway: Agilon Health has expanded its partnership with The Jackson Clinic by integrating it into its Senior Health Connect Accountable Care Organizations (ACOs). This collaboration is expected to enhance healthcare delivery by leveraging The Jackson Clinic's extensive network of over 130 providers across various specialties. The partnership aims to empower physicians and improve patient outcomes in the community. Market sentiment Analysis. Positive factors. * Expansion of partnership enhances healthcare services. * The Jackson Clinic is a large and reputable organization. * Collaboration aims to empower physicians and improve patient care. WESTERVILLE, OH- agilon health (NYSE: AGL), the trusted partner empowering physicians to transform health care in its communities, today announced the expansion of its partnership with The Jackson Clinic, which will join one of agilon's Senior Health Connect Accountable Care Organizations (ACOs). The Jackson Clinic, one of Tennessee's largest independent physician organizations, includes more than 130 providers representing 24 specialties and subspecialties at 13 locations serving nine counties in the Jackson area. In 2022, the clinic began a long-term partnership with agilon to transition to a full-risk, value-based care model currently supporting approximately 8,000 senior Medicare Advantage patients. Now, The Jackson Clinic is joining agilon's Senior Health Connect ACO and is expected to help reach approximately 9,000 more Traditional Medicare beneficiaries across the communities it serves. The ACO participates in the Medicare Shared Savings Program (MSSP) and is expected to provide The Jackson Clinic with additional support to deliver more coordinated, personalized, patient-centered care focused on prevention, earlier intervention and improving outcomes while reducing unnecessary healthcare spending. agilon brings extensive experience supporting physicians through accountable care models. Since 2021, agilon's ACOs have generated more than $510 million in gross savings, including $125 million in savings to the Medicare Trust Fund, demonstrating the ability to improve outcomes while reducing costs. In 2024, the most recent year for which quality data is available, agilon's ACOs achieved an average quality score of 96%. Four of them earned perfect quality scores, and five were recognized as high performers for achieving exceptional results across all quality measures. "We are honored to enter this next phase of our partnership with The Jackson Clinic through Senior Health Connect ACO and continue our shared work to help physicians improve care for seniors," said Tim O'Rourke, chief executive officer of agilon health. "Accountable care is designed to help physicians look beyond a single visit and fully understand each patient's needs. Together, we can place greater emphasis on prevention, earlier intervention and effective chronic disease management to improve care quality, health outcomes and the patient experience, making a meaningful difference for people and communities across Tennessee." Founded in 2016, agilon partners with more than 30 physician groups and health systems to help them succeed in full-risk, value-based care for Medicare Advantage and fee-for-service innovation models. Through its next-generation technology and AI-enabled platforms, agilon transforms data from across the healthcare ecosystem into actionable insights that help physicians anticipate patient needs, intervene earlier and close care gaps. Specialized clinical pathways for chronic conditions such as heart failure, chronic obstructive pulmonary disease (COPD) and dementia further equip physicians to address complex patient needs and deliver more proactive, coordinated care at scale. "We are deeply connected to the patients and communities we serve, and joining Senior Health Connect ACO will help us provide more personalized care for Medicare patients while preserving the local, physician-led approach that defines The Jackson Clinic," said Nancy Utley, MD, chief quality officer at The Jackson Clinic. "With agilon's technology, insights and operational support, we can identify patients' needs earlier, help patients manage chronic conditions more effectively and make care easier to navigate. Just as importantly, care decisions remain between patients and the physicians who know them best." Building on a strong track record in ACO models, agilon health is well positioned to extend that momentum alongside its physician partners as accountable care evolves. The company's demonstrated success in driving quality outcomes and generating shared savings under ACO models provides a proven foundation as participating ACOs look to the future. With its long-term care model, deep primary care relationships and infrastructure built for value-based performance, agilon and its ACO partners are poised to capture significant opportunities for continued growth and strong performance across ACO models. This continuity reflects agilon's enduring commitment to helping community physicians thrive in accountable care and improve outcomes for the seniors they serve. About The Jackson Clinic. The Jackson Clinic is one of Tennessee's largest independent physician organizations which brings together the knowledge of more than 130 providers in 24 specialties and subspecialties, providing care to patients at 13 locations across nine counties in the Jackson area. The Jackson Clinic medical staff has privileges at hospitals throughout West Tennessee. Their physicians are supported by state-of-the-art technology in diagnostic testing departments, which include: Laboratory, Radiology (Ultrasound, CAT Scan, Dexascan, Bone Densitometry, Nuclear Medicine, Magnetic Resonance Imaging, and Mammography), Stereotactic Biopsy, Pulmonary Function Analysis, Arterial Blood Gases, Electrocardiography and Vascular Ultrasound. The clinic's mission is to enhance the lives of West Tennesseans by healing individual patients and promoting wellness for all through a collaborative affordable, and comprehensive healthcare system. Visitjacksonclinic.comto learn more or connect with BiopharmaWatch onFacebook,InstagramandYouTube. About agilon health. agilon health is the trusted partner empowering physicians to transform health care in its communities. Through its partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process and access to a peer network of approximately 2,300 primary care physicians (PCPs) that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system BiopharmaWatch need - one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in approximately 30 communities and is here to help more of its nation's leading physician groups and health systems have a sustained, thriving future. For more information, visit agilonhealth.com and connect with BiopharmaWatch on LinkedIn. The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document. Forward looking statements. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or its future financial or operating performance and may be identified by the use of words such as "may," "will," "expect," "believe," "intend," "anticipate," "seek," "target," "plan," "estimate," "potential," "could," "would," "should," and similar expressions and the negatives of those terms. Examples of forward-looking statements include, among other things: the benefits of our expanded partnership with The Jackson Clinic, our ACO model and our data uses with AI. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially include those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the Securities and Exchange Commission. These documents contain and identify important factors that could cause actual results to differ materially from those contained in the Company's projections or forward-looking statements. Except as required by law, the Company undertakes no obligation to update any forward-looking statements, which speak only as of the date they are made. Contacts. Investor contacts. Media contact. The postagilon health and The Jackson Clinic advance their partnership through Senior Health Connect ACOappeared first onagilon health. Frequently asked questions. What is the purpose of the partnership between Agilon Health and Jackson Clinic? The partnership aims to enhance healthcare services through the Senior Health Connect ACO. How many providers are at The Jackson Clinic? The Jackson Clinic includes over 130 providers across 24 specialties. Where is The Jackson Clinic located? The Jackson Clinic operates at 13 locations in Tennessee. What is an Accountable Care organization (ACO)? An ACO is a group of healthcare providers that work together to improve patient care.

BioPharma Watch
Aug 27th, 2026
agilon health announces revised presentation time at the 2026 Jefferies Healthcare Services and Technology Conference.

agilon health announces revised presentation time at the 2026 Jefferies Healthcare Services and Technology Conference. Key Takeaway: Agilon Health has announced a change in the timing of its presentation at the 2026 Jefferies Healthcare Services and Technology Conference. The management team will now participate in a fireside chat scheduled for 4:00 PM ET on September 14, 2026. Investors can access the presentation through a webcast. Market sentiment analysis. Positive factors. * Agilon Health is actively engaging with investors. * The company is participating in a significant healthcare conference. * The revised presentation time allows for broader audience access. WESTERVILLE, Ohio-(BUSINESS WIRE)-agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in its communities, today announced that its management team will now participate in a fireside chat at the 2026 Jefferies Healthcare Services and Technology Conference at 4:00pm ET on Monday, September 14, 2026. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section o Frequently asked questions. What is the new presentation time for Agilon Health? The new presentation time is 4:00 PM ET on September 14, 2026. Where can I listen to the Agilon Health presentation? The presentation can be accessed via a webcast in the 'Events & Presentations' section. What type of event is Agilon Health participating in? Agilon Health is participating in the 2026 Jefferies Healthcare Services and Technology Conference.

Recently Posted Jobs

Sign up to get curated job recommendations

agilon health is Hiring for 10 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs